The global Myasthenia
Gravis Disease Market is anticipated to
exceed USD 2,538.6 Million by 2026 according to a new research published by
Polaris Market Research. In 2017, the diagnosis segment dominated the global
market, in terms of revenue. Myasthenia gravis disease is characterized by
rapid fatigue and weakness of any muscles under person’s voluntary control.
Though myasthenia gravis can affect people of any age, it’s more common in
women younger than 40 and in men older than 60. In General, myasthenia gravis
disease is caused by a breakdown in the normal communication between muscles
and nerves. There is no accurate cure for MG disease, however, appropriate and
early treatment can help to control symptoms, such as double vision,
difficulties with speech, chewing, swallowing and breathing, weakness of arm or
leg muscles, and drooping of eyelids.
The global Myasthenia Gravis
Disease market is majorly driven by the need to prevent declining quality of
life owing to myasthenia gravis disease. Moreover, growing R&D initiatives
for novel therapies are another factor boosting the market growth. In addition,
key players are also involved in innovative research to launch the affordable
therapeutics for such disease. However, the unfamiliarity with early symptoms
as well as signs and high cost associated with the treatment are factors
hampering the market growth.
Download
Sample Copy @ https://www.polarismarketresearch.com/industry-analysis/myasthenia-gravis-disease-market/request-for-sample
The
global Myasthenia Gravis Disease Market is segmented on the basis of diagnosis,
treatment, end-user, and region. On the basis of diagnosis, the market is
categorized into Imaging, Blood Tests, Electrodiagnostic, and Edrophonium Test.
The imaging segment is further bifurcated into X-ray, Computed Tomography (CT),
Magnetic Resonance Imaging (MRI), and others. On the basis of treatment, the
market is segmented into Medication, Surgery, and HSCT. The end-user is further
segmented in to Hospitals, Clinics, and Academic Research Institutes.
Geographically, North America
accounted for the largest share in the global Myasthenia Gravis Disease Market
in 2017. The major factors accounted for the high market growth includes high
occurrence of disease such in North America.
Get
Special Discount On Complete Report @ https://www.polarismarketresearch.com/industry-analysis/myasthenia-gravis-disease-market/request-for-discount-pricing
Moreover,
Asia Pacific is estimated to generate the lucrative market growth during the
forecast period. Growing initiatives by government and private organizations
for generating novel control treatment are factors estimated to propel the
myasthenia gravis disease market growth in Asia Pacific. In addition,
increasing awareness about neuromuscular disorders and vast improvement are
boosting the market growth in APAC.
The leading
companies profiled in the Myasthenia Gravis Disease Market report include
Alexion Pharmaceutical Inc., Avadel Pharmaceuticals plc, CSL Behring, Grifols
S.A., Baxter International Inc., Shire plc, Novartis AG, F. Hoffmann-La Roche
AG, Takeda Pharmaceutical Company Limited, and Valeant Pharmaceuticals
International Inc. These companies launch new products and collaborate with
other market leaders to innovate and launch new products to meet the increasing
needs and requirements of consumers.
About Polaris Market Research
Polaris Market Research is a global market research and
consulting company. The company specializes in providing exceptional market
intelligence and in-depth business research services for our clientele spread
across different enterprises.
Contact Us:
Polaris Market Research
Phone: 1–646–568–9980
Email: sales@polarismarketresearch.com
